bicitropeptide

01/13/1979 - "In the bicitropeptide group 100% of the patients in the duodenal ulcer group and 95,2% in the gastric ulcer group responded to treatment (improved or healed). "
02/13/1982 - "In a double-blind study comprising 50 patients with endoscopically proven uncomplicated duodenal ulcers a powder formulation of bicitropeptide (BCP-Compound) was found to be superior to placebo. "
02/13/1982 - "Bicitropeptide powder and placebo in the treatment of duodenal ulcers. "
02/14/1981 - "Bicitropeptide and cimetidine in the treatment of duodenal ulcers."
10/18/1980 - "Bicitropeptide and cimetidine in the treatment of duodenal ulcers. "

01/13/1979 - "In the bicitropeptide group 100% of the patients in the duodenal ulcer group and 95,2% in the gastric ulcer group responded to treatment (improved or healed). "
10/18/1980 - "Ultrastructural changes in gastric ulcers after bicitropeptide and cimetidine treatment."
01/13/1979 - "Bicitropeptide was significantly better than antacid and placebo at 3 and 6 weeks for treatment of both duodenal and gastric ulcers. "
10/18/1980 - "Ultrastructural studies were conducted on biopsy specimens taken by endoscopy from the edge of gastric ulcers in the distal part of the stomach of 9 patients before and after treatment with either bicitropeptide or cimetidine. "

10/18/1980 - "Patients were followed up 3 months after the ulcers healed, and 44% who had been on bicitropeptide and 72% on cimetidine had active ulcers (no significant difference). "
10/18/1980 - "After the administration of bicitropeptide, 77% of ulcers had completely healed and 25% had partially healed, and after treatment with cimetidine 38% had completely healed and 38% had partially healed (chi 2 = 6,316; P < 0,025). "
11/01/1979 - "Bismuth blood and urine levels obtained from patients after administration of a new anti-ulcer drug (Bicitropeptide) in a well controlled clinical trial are discussed and suggest that that this bismuth containing drug behaves pharmacologically in a manner similar to the inorganic bismuth salts in man, low bismuth blood levels and the absence of toxic side effects being conspicuous features of the drug. "
02/06/1982 - "Drugs utilized were (patient numbers in brackets): a new histamine H2-receptor antagonist ranitidine (25) v. placebo (22), the colloidal bismuth ulcer-coating preparation bicitropeptide (24) v. cimetidine (26), the tricyclic antidepressant trimipramine (20) v. placebo (19), and the disaccharide coating preparation sucralfate (29) v. placebo (28). "